ABSTRACT
INTRODUCTION

70
Invasive pulmonary aspergillosis (IPA) is a leading cause of morbidity and mortality in
MATERIALS AND METHODS
93
Organisms. Four A. fumigatus isolates (DPL, EMFR S678P, F16216, and F11628) 94 were chosen for the current study including two wild-type at Cyp51 (one wild-type and 95 one Fks1 mutant) and two Cyp51 mutants. Isolates DPL, F16216, and F11628 are 96 clinical isolates, whereas EMFR S678P is a laboratory engineered mutant. The two Table 2 ). The doses were 148 selected to vary the expected result from zero effect to maximal effect or the highest 149 tolerated dose. Controls were utilized for each experiment and included a start and end 150 of therapy. Four mice were used for each treatment regimen and control group.
151
Therapy was initiated 2 hours after infection. At the time of sacrifice of moribund 152 animals or at study endpoint (7 d), lungs were aseptically harvested and processed for 153 quantitative PCR (qPCR) as described below.
155
Lung Processing and Organism Quantitation. Processing and quantitation of lung 156 burden was performed based upon previously described protocols (29, 30) . Briefly, at in a sterile bead beating tube (Sarstedt, Newton, NC) with 700 μl of 425-600 μm acid- 
178
The Fks1 mutation (S678P) was not located in the primer:probe area of the genome.
179
The primer:probe set was validated for all isolates by comparing the kinetics and
180
quantitative results for known quantities of conidia over the dynamic range (10 2 -10 8 )
known quantities of conidia. Organism burden was reported as conidial equivalents
184
(C.E.) per ml of primary lung homogenate (log 10 C.E./ml lung homogenate). MICs (Figure 1 ). Posaconazole treatment against the more susceptible strains resulted 278 in more than a 3-log 10 C.E./ml reduction in lung burden. However, as shown in Figure   279 2, caspofungin monotherapy exhibited only modest in vivo effect in this animal model for 280 each of the strains. The posaconazole static dose and 1-log kill dose (when achieved)
281
was determined for each isolate and is shown in mg/kg/24 h was needed to produce a 1-log reduction in burden compared to that at the 287 start of therapy. Caspofungin therapy did not produce the stasis or 1 log reduction 288 endpoints for any of the four isolates.
289
The posaconazole free drug AUC/MIC exposures were determined for each Table 4 . There were no significant changes in 
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